Won't you come on in?: How to favor lymphocyte infiltration in tumors

OncoImmunology

Volumn 1, Issue 6, 2012, Pages 986-988

  Bellone, Matteo ^a   Calcinotto, Arianna ^a,b   Corti, Angelo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Cell trafficking; Endothelial cells; Immunotherapy; T cells; Tumor

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE; NGR TNF PROTEIN; TUMOR NECROSIS FACTOR DERIVATIVE; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CELL ACTIVATION; CELL INTERACTION; CLONAL ANERGY; CYTOKINE RELEASE; ENDOTHELIUM CELL; LYMPHOCYTIC INFILTRATION; MELANOMA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 84872834025     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20213     Document Type: Article

References (10)

1. Corti A, Pastorino F, Curnis F, Arap W, Ponzoni M, Pasqualini R. Targeted drug delivery and penetration into solid tumors. Med Res Rev 2011; In press; PMID:21287572.
2. Corti A, Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A. Enhancement of tumor necrosis factoralpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000; 18:1185-90; PMID:11062439; http://dx.doi.org/10.1038/81183.
3. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010; 10:505-14; PMID:20574450; http://dx.doi.org/10.1038/nrc2868.
4. Bellone M, Mondino A, Corti A. Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer. Trends Immunol 2008; 29:235- 41; PMID:18375183; http://dx.doi.org/10.1016/j.it.2008.02.003.
5. Calcinotto A, Grioni M, Jachetti E, Curnis F, Mondino A, Parmiani G, et al. Targeting TNFα to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy. J Immunol 2012; 188:2687-94; PMID:22323546; http://dx.doi.org/10.4049/jimmunol. 1101877.
6. Dirkx AE, oude Egbrink MG, Castermans K, van der Schaft DW, Thijssen VL, Dings RP, et al. Antiangiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J 2006; 20:621- 30; PMID:16581970; http://dx.doi.org/10.1096/fj.05-4493com.
7. Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res 2006; 12:6808-16; PMID:17121902; http://dx.doi.org/10.1158/1078- 0432.CCR-06-1558.
8. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70:6171-80; PMID:20631075; http://dx.doi.org/10.1158/0008-5472.CAN-10-0153.
9. Manning EA, Ullman JG, Leatherman JM, Asquith JM, Hansen TR, Armstrong TD, et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immunebased mechanism. Clin Cancer Res 2007; 13:3951-9; PMID:17606729; http://dx.doi.org/10.1158/1078- 0432.CCR-07-0374.
10. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62; PMID:15637262; http://dx.doi. org/10.1126/science.1104819.